Page 12 - Crispr News Today

People with the genetic disease have new opportunities to eliminate their symptoms, but the treatments come with obstacles that limit their reach.

The FDAs approval of Casgevy, which uses the Nobel Prize-winning gene-editing therapy to treat patients with sicke cell disease, opens the door to many other therapies.

The FDA has approved a gene-editing therapy for sickle cell disease (SCD) for the first time.

There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.

Pioneering biochemist Jennifer Doudna sat down with WIRED’s Emily Mullin to talk about the future of Crispr.

A decision by the F.D.A. this week could change care for thousands of Americans living with sickle cell.

FDA soon rules if gene-editing CRISPR drug Exa-cel can be used commercially to treat sickle cell disease, opening door to many other therapies.

The recent publication in Science by Mogila, Tamulaitiene et al. represents a continuation of the successful scientific research conducted by Gintautas Tamulaitis' group.

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description We begin this episode by discussing our article of the week from the New England

Jennifer Doudna answers our questions.